Anti-CD20 Immunocytokine, scFv-Fc (Rituximab)-IL2 (ACFP-SH133)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 scFv-Fc to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD20 as well as the biological activity of IL2. This 2B8-Fc-hIL2 was at least equivalent to the commercial molecule in both binding to Daudi cells and activation of ADCC and may represent a promising plant-derived biopharmaceutical for the treatment of NHLs. This immunocytokine was designed for treating leukemias, lymphomas, rheumatoid arthritis, and other autoimmune diseases.
Specifications
- Target
- CD20
- Molecule Class
- scFv-Fc-IL2
- Species Reactivity
- Human
- Host
- Chimeric (Human-Mouse)
- Expression Host
- CHO
- Clone
- Rituximab
- Related Disease
- Leukemias, Lymphomas, Rheumatoid arthritis, and other autoimmune diseases
- Cytokines 1
- IL2
- Cytokines 1 Description
- Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- MS4A1; membrane-spanning 4-domains; subfamily A; member 1; B1; S7; Bp35; CD20
- Entrez Gene ID
- 931
- UniProt ID
- A0A024R507
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: